Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
PATIENT Act of 2023
Client: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement
Medicare Patient Access to Cancer Treatment Act
Client: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2026 · second_quarter · Q2
Issues related to the President's federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.
All legislation related to Medicare site of service payment policy changes; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants
Source: Senate LDA
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement
Health Care Price Transparency Act of 2023
Client: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement
SITE Act
Client: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; Issues relating to clinical trials at FDA and the ability for patients to be able to access trials earlier in their treatment journey;
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2026 · first_quarter · 1A
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; the future of global health programs;
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants.
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. The impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions; Funding included in the CR packages that were passed.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2026 · first_quarter · Q1
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. The impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions; Funding included in the CR packages that were passed.
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants.
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; the future of global health programs;
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2025 · first_quarter · 1A
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve.
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2025 · fourth_quarter · Q4
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; the future of global health programs;
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants.
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. The impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions; Funding included in the CR packages that were passed.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2025 · third_quarter · Q3
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2025 · second_quarter · Q2
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2025 · first_quarter · Q1
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve.
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2024 · fourth_quarter · Q4
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Continuation of medicare reimbursement for tele-health services.
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues relarted to the reorganization of NIH, ARPA-H.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2024 · third_quarter · Q3
Issues related to the cost of pharmaceuticals; pharmacy benefit managers, white bagging, clear bagging and brown bagging. Legislation that includes drug administration reimbursement changes.
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. Continuation of medicare reimbursement for tele-health services.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2024 · second_quarter · Q2
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property. Events surrounding Change healthcare cyber attack.
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues relarted to the reorganization of NIH, ARPA-H.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2024 · first_quarter · Q1
Issues related to visa programs sponsored by the US Department of State
Issues related to Graduate Medical Education programs
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2023 · fourth_quarter · Q4
Issues related to Graduate Medical Education programs
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property;
Issues related to visa programs sponsored by the US Department of State
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2023 · fourth_quarter · Q4
Issues related to Graduate Medical Education programs
Issues related to visa programs sponsored by the US Department of State
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2023 · third_quarter · Q3
Funding for and location of the Advanced Research Projects Agency for Health (ARPA-H)
Issues related to visa programs sponsored by the US Department of State
Issues related to Graduate Medical Education programs
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2023 · second_quarter · Q2
Issues related to Graduate Medical Education programs
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Funding for ARPA-H and the CancerMoonshot Program
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Proposed hospital site of service payment changes.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2023 · first_quarter · Q1
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Funding for ARPA-H and the CancerMoonshot Program
Funding for and location of the Advanced Research Projects Agency for Health
Issues related to Graduate Medical Education programs
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2022 · fourth_quarter · Q4
Development and funding for the Advanced Research Projects Agency for Health
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research; the omnibus
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services; Medicare Advantage and preauthorization;
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2022 · third_quarter · Q3
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services; Medicare Advantage and preauthorization;
Development and funding for the Advanced Research Projects Agency for Health
Legislation related to foreign influence of American research and protection of intellectual property
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2022 · second_quarter · Q2
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research
Development and funding for the Advanced Research Projects Agency for Health
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2022 · first_quarter · Q1
Legislation related to foreign influence of American research and protection of intellectual property
COVID relief for healthcare providers and hospitals Development and funding for the Advanced Research Projects Agency for Health
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2021 · fourth_quarter · Q4
COVID relief for healthcare providers and hospitals Development and funding for the Advanced Research Projects Agency for Health
Legislation related to foreign influence of American research and protection of intellectual property
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2021 · third_quarter · Q3
Legislation related to foreign influence of American research and protection of intellectual property
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
COVID relief for healthcare providers and hospitals Funding for research recovery Development and funding for the Advanced Research Projects Agency for Health
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2021 · second_quarter · Q2
COVID relief for healthcare providers and hospitals Funding for research recovery
FY22 appropriation bills related to biomedical research funding; healthcare delivery, training and education
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2021 · first_quarter · Q1
Legislation related to foreign influence of American research
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
COVID relief for healthcare providers and hospitals Funding for research recovery
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2020 · fourth_quarter · Q4
Any legislation addressing the COVID-19 pandemic related to reimbursing eligible health care providers for health care-related expenses or lost revenue; funds and flexibility for expanding capacity for COVID-19 testing; funds and flexibility for the preservation and recovery of research; funds for PPE; funds and flexibility for coverage of COVID-19 testing and treatment; funds and flexibility for the continued use and expansion of telehealth.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals, cancer centers, and providers.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2020 · third_quarter · Q3
Any legislation addressing the COVID-19 pandemic related to reimbursing eligible health care providers for health care-related expenses or lost revenue; funds and flexibility for expanding capacity for COVID-19 testing; funds and flexibility for the preservation and recovery of research; funds for PPE; funds and flexibility for coverage of COVID-19 testing and treatment; funds and flexibility for the continued use and expansion of telehealth.
Discussions related to the importance of promoting and protecting the nation's bio-economy.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2020 · second_quarter · Q2
Any legislation addressing the COVID-19 pandemic related to the research and development of pharmaceuticals related to COVID-19; funds and flexibility for the preservation and recovery of research.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals, cancer centers, and providers.
Any legislation addressing the COVID-19 pandemic related to reimbursing eligible health care providers for health care-related expenses or lost revenue; funds and flexibility for expanding capacity for COVID-19 testing; funds and flexibility for the preservation and recovery of research; funds for PPE; funds and flexibility for coverage of COVID-19 testing and treatment; funds and flexibility for the continued use and expansion of telehealth.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2020 · first_quarter · Q1
Any legislation addressing the COVID-19 pandemic. The CARES Act: Inclusion of relief funds for hospitals and providers; medicare sequester relief; funding for loss of research operations; flexibility in the use of telehealth, Medicare payments for COVID patients. Any legislation and regulations addressing surprise billing and the impact on providers, including hospitals.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals, cancer centers, and providers.
Discussions related to the importance of promoting and protecting the nation's bio-economy.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2019 · fourth_quarter · Q4
Any legislation and regulations addressing surprise billing and the impact on providers, including hospitals.
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Discussions related to the importance of promoting and protecting the nation's bio-economy.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2019 · third_quarter · Q3
Any legislation and regulations addressing drug pricing.
Any legislation and regulations addressing surprise billing and the impact on providers, including hospitals.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals and cancer centers.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2019 · second_quarter · Q2
Increased federal research funding in appropriations bills, particularly funding for the National Institutes of Health.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals and cancer centers.
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2019 · first_quarter · Q1
Increased federal research funding in FY 19 appropriations bills, particularly funding for the National Institutes of Health.
Issues related to Nurse Practitioners and scope of work and licensure.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals and cancer centers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER via THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
2019 · first_quarter · RR
research funding Medicare reimbursement healthcare issues
research funding Medicare reimbursement healthcare issues
research funding Medicare reimbursement healthcare issues
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and legislation related to drug discovery, clinical trials and commercialization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and legislation related to drug discovery, clinical trials and commercialization.
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property. Events surrounding Change healthcare cyber attack.
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues relarted to the reorganization of NIH, ARPA-H.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and legislation related to drug discovery, clinical trials and commercialization.
Issues related to the cost of pharmaceuticals; pharmacy benefit managers, white bagging, clear bagging and brown bagging. Legislation that includes drug administration reimbursement changes.
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the cost of pharmaceuticals; pharmacy benefit managers, white bagging, clear bagging and brown bagging
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products.
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Funding for ARPA-H and the CancerMoonshot Program
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property;
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property;
Funding for and location of the Advanced Research Projects Agency for Health
Issues related to visa programs sponsored by the US Department of State
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to visa programs sponsored by the US Department of State
Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization
Issue related to cyber security; vulnerability of healthcare providers to ransomeware attacks; theft of intellectual property;
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation related to foreign influence of American research and protection of intellectual property
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; payment coverage for cancer services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation related to foreign influence of American research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussions related to the importance of promoting and protecting the nation's bio-economy.
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Any legislation addressing the COVID-19 pandemic related to the research and development of pharmaceuticals related to COVID-19; funds and flexibility for the preservation and recovery of research.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Any legislation addressing the COVID-19 pandemic related to the research and development of pharmaceuticals related to COVID-19; funds and flexibility for the preservation and recovery of research.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals, cancer centers, and providers.
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Discussions related to the importance of promoting and protecting the nation's bio-economy.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Any legislation addressing the theft of scientific research or intellectual property. Any legislation on foreign influence on extramural research.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Any legislation and regulations addressing drug pricing.
Any legislation and regulations potentially or directly impacting Medicare reimbursement for hospitals and cancer centers. Proposed regulations that impact Proton Therapy reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Technology Policy (OTP), SENATE
Increased federal research funding in appropriations bills, particularly funding for the National Institutes of Health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
research funding Medicare reimbursement healthcare issues
research funding Medicare reimbursement healthcare issues